Clinical Impact of Serum CRP Levels on Advanced HCC Treated With Durvalumab and Tremelimumab: A Multicentre Study
Liver International · 2025
DOI: 10.1111/liv.70192 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift Liver International, 2025. Verfasst von Takeshi Hatanaka und 48 weiteren Autor:innen. Beteiligte Einrichtung: Department of Gastroenterology, Gunma Saiseikai Maebashi Hospital, Maebashi, Japan. Hauptthemen laut MEDLINE: C-Reactive Protein, Carcinoma, Hepatocellular, Liver Neoplasms, Antibodies, Monoclonal, Humanized. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 30 Literaturangaben.
Abstract (Originalsprache)
Aim
This study aimed to evaluate the therapeutic efficacy and prognostic significance of C‐reactive protein (CRP) in patients with advanced hepatocellular carcinoma (HCC) receiving durvalumab and tremelimumab (Dur/Tre).
Methods
A total of 167 patients treated with Dur/Tre between March 2023 and March 2024 in Japanese hospitals were included in this retrospective multicentre study. Patients were divided into two groups based on pre‐treatment serum CRP levels: the low‐CRP group (< 1 mg/dL, n = 106) and the high‐CRP group (≥ 1 mg/dL, n = 61).
Results
The median age of the cohort was 74.0 years (interquartile range, 67.5–79.5), and 139 patients (83.2%) were male. The median progression‐free survival (PFS) was 3.6 months (95% CI: 2.6–5.4) in the low‐CRP group and 2.4 months (95% CI: 1.9–4.1) in the high‐CRP group, with statistical significance ( p = 0.02). The median overall survival (OS) was not reached in the low‐CRP group, with a 1‐year survival rate of 64.7% (95% CI: 49.0–76.7), while it was 7.9 months (95% CI: 5.8–11.8) in the high‐CRP group. The low‐CRP group demonstrated significantly better survival outcomes compared to the high‐CRP group ( p < 0.001). Multivariate analysis identified serum CRP level as an independent predictive factor for both PFS and OS ( p = 0.04 and < 0.001, respectively). No significant differences in immune‐related adverse events were observed between the two groups.
Conclusions
Serum CRP may serve as a prognostic biomarker in HCC patients receiving Dur/Tre, with a potential association with treatment efficacy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Gastroenterology, Gunma Saiseikai Maebashi Hospital, Maebashi, Japan.
- Department of Gastroenterology, Hanwa Memorial Hospital, Osaka, Japan.
- Gastroenterology Center, Ehime Prefectural Central Hospital, Matsuyama, Japan.
- Division of Gastroenterology, Department of Internal Medicine, Kobe University Graduate School of Medicine, Kobe, Japan.
- Department of Gastroenterology and Metabology, Ehime University Graduate School of Medicine, Touon, Japan.
- Department of Gastroenterology, Okayama City Hospital, Okayama, Japan.
ORCID-Profile: Takeshi Hatanaka, Yutaka Yata, Atsushi Hiraoka, Toshifumi Tada, Kazuya Kariyama, Joji Tani, Koichi Takaguchi, Ei Itobayashi, Satoru Kakizaki, Kunihiko Tsuji, Toru Ishikawa, Kazuto Tajiri, Hidenori Toyoda, Takashi Nishimura, Kazuhito Kawata, Hisashi Kosaka, Atsushi Naganuma, Hideko Ohama, Hidekatsu Kuroda, Kazunari Tanaka, Fujimasa Tada, Kazuhiro Nouso, Asahiro Morishita, Akemi Tsutsui, Hirayuki Enomoto, Masaki Kaibori, Yoichi Hiasa, Masatoshi Kudo, Takashi Kumada
Zitieren
APA
Hatanaka, T., Yata, Y., Hiraoka, A., Tada, T., Hirooka, M., Kariyama, K., Tani, J., Atsukawa, M., Takaguchi, K., Itobayashi, E., Kakizaki, S., Fukunishi, S., Tsuji, K., Ishikawa, T., Tajiri, K., Toyoda, H., Koshiyama, Y., Ogawa, C., Nishikawa, H., …, & Real‐life Practice Experts for HCC (RELPEC) Study Group, HCC 48 Group (hepatocellular carcinoma experts from 48 clinics in Japan) (2025). Clinical Impact of Serum CRP Levels on Advanced HCC Treated With Durvalumab and Tremelimumab: A Multicentre Study. Liver International. https://doi.org/10.1111/liv.70192
Vancouver
Hatanaka T, Yata Y, Hiraoka A, Tada T, Hirooka M, Kariyama K, et al. Clinical Impact of Serum CRP Levels on Advanced HCC Treated With Durvalumab and Tremelimumab: A Multicentre Study. Liver International. 2025. doi:10.1111/liv.70192
BibTeX
@article{Hatanaka2025,
author = {Hatanaka, Takeshi and Yata, Yutaka and Hiraoka, Atsushi and Tada, Toshifumi and Hirooka, Masashi and Kariyama, Kazuya and Tani, Joji and Atsukawa, Masanori and Takaguchi, Koichi and Itobayashi, Ei and Kakizaki, Satoru and Fukunishi, Shinya and Tsuji, Kunihiko and Ishikawa, Toru and Tajiri, Kazuto and Toyoda, Hidenori and Koshiyama, Yuichi and Ogawa, Chikara and Nishikawa, Hiroki and Nishimura, Takashi and Kawata, Kazuhito and Kosaka, Hisashi and Matsui, Kosuke and Naganuma, Atsushi and Tanaka, Hironori and Ohama, Hideko and Kuroda, Hidekatsu and Matono, Tomomitsu and Aoki, Tomoko and Ochi, Hironori and Imai, Michitaka and Nakamura, Shinichiro and Kanayama, Yuki and Tanaka, Kazunari and Tada, Fujimasa and Yoshida, Osamu and Nouso, Kazuhiro and Morishita, Asahiro and Tsutsui, Akemi and Nagano, Takuya and Itokawa, Norio and Okubo, Tomomi and Arai, Taeang and Enomoto, Hirayuki and Kaibori, Masaki and Hiasa, Yoichi and Kudo, Masatoshi and Kumada, Takashi and Real‐life Practice Experts for HCC (RELPEC) Study Group, HCC 48 Group (hepatocellular carcinoma experts from 48 clinics in Japan), Real‐life Practice Experts for HCC (RELPEC) Study Group, HCC 48 Group (hepatocellular carcinoma experts from 48 clinics in Japan)},
title = {Clinical Impact of Serum CRP Levels on Advanced HCC Treated With Durvalumab and Tremelimumab: A Multicentre Study},
journal = {Liver International},
year = {2025},
doi = {10.1111/liv.70192}
}
EUVIMED